News

Filter

Current filters:

Generics

1226 to 1235 of 96906 results

Amgen announces positive results for Phase III trial of Kyprolis in relapsed multiple myeloma

Amgen announces positive results for Phase III trial of Kyprolis in relapsed multiple myeloma

04-08-2014

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx, say their Phase…

AmgenKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalResearchRobert BradwayUSA

Taiho Pharma drops orantinib Ph III trial

Taiho Pharma drops orantinib Ph III trial

04-08-2014

Japanese drugmaker Taiho Pharmaceutical says it is terminating a Phase III clinical trial (ORIENTAL trial)…

Hepatocellular carcinomaHepatologyJapanOncologyorantinibPharmaceuticalResearchS-1TACETaiho PharmaceuticalTSU-68

Vernalis achieves research milestones in Servier oncology collaborations

Vernalis achieves research milestones in Servier oncology collaborations

04-08-2014

UK biopharmaceutical company Vernalis and Servier, France’s largest independent drugmaker, say that…

FinanceFinancialFranceIan GarlandOncologyPharmaceuticalResearchServierUKVernalis

Bristol-Myers Squibb form company with Allied Minds for research and preclinical development

Bristol-Myers Squibb form company with Allied Minds for research and preclinical development

04-08-2014

US drug major Bristol-Myers Squibb and science and technology development company Allied Minds are to…

BiotechnologyBristol-Myers SquibbDrug discoveryResearchUSA

Eisai's Fycompa launches in Belgium for partial-onset seizures

Eisai's Fycompa launches in Belgium for partial-onset seizures

04-08-2014

Fycompa (perampanel), an epilepsy drug developed by Japanese dug major Eisai, launches today in Belgium.

BelgiumCentral nervous systemEisaiEpilepsyFycompaJapanNeurologicalPharmaceuticalRegulation

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

02-08-2014

The US Food and Drug Administration on Friday approved Lumizyme (alglucosidase alfa) for treatment of…

BiotechnologyGenzymeLumizymeMyozymeRare diseasesRegulationSanofiUSA

1226 to 1235 of 96906 results

Back to top